Asked by: Ben Lake (Plaid Cymru - Ceredigion Preseli)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential impact of the regime of discounts applied to meat charges incurred by undertaking inspection obligations under Official Controls Regulations on the small abattoir industry in Wales.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
On 28 February 2025, further to engagement with industry representative bodies, the Food Standards Agency published the 2025/26 charge rates for inspections in meat premises in England and Wales. As in previous years, charges in 2025/26 will be offset by a taxpayer-funded discount scheme which will provide the greatest proportional support to smaller abattoirs, and will therefore benefit the small abattoir industry in Wales. A separate exercise is being conducted in respect of 2025/26 charges for abattoirs in Northern Ireland.
Asked by: Ben Lake (Plaid Cymru - Ceredigion Preseli)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will take steps to include reform of inherited cardiac conditions in the 10-year plan for the NHS.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The 10-Year Health Plan will deliver the three big shifts the National Health Service needs to be fit for the future: from hospital to community, from analogue to digital, and from sickness to prevention. All of these are relevant to improving cardiac health in all parts of the country.
More tests and scans delivered in the community, better joint working between services, and greater use of apps and wearable technology will all help people manage their long-term conditions, including cardiac disease, closer to home. Moving from sickness to prevention will help us provide treatment earlier, rather than only intervening when conditions deteriorate.
NHS England has published a national service specification for inherited cardiac conditions that covers patients who often present as young adults with previously undiagnosed cardiac disease or families requiring follow up due to a death from this cause. NHS England is currently reviewing this service specification in line with the national service specification methods review process. The specification is available at the following link:
https://www.england.nhs.uk/wp-content/uploads/2017/11/cardiology-inherited-cardiac-conditions.pdf
Asked by: Ben Lake (Plaid Cymru - Ceredigion Preseli)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the Medical Certificate of Cause of Death (England and Wales) Regulations 2024 on the timely registration of deaths.
Answered by Andrew Gwynne
The Government is monitoring the impact of the death certification reforms, including the Medical Certificate of Cause of Death Regulations 2024, which came into legal effect on 9 September 2024. The median time taken to register a death since the introduction of the reforms in England and Wales has typically been eight days. This figure is for all deaths, as it includes those certified by a doctor and those investigated by a coroner. The median time taken to register a death varies depending on the type of certification. Deaths certified by a doctor, that comprise approximately 80% of deaths registered each week, have typically had a median time to registration of seven days. It’s important to note that the medical examiner system was active on a non-statutory basis before the introduction of the statutory system on 9 September 2024, and this makes direct before and after comparisons challenging to draw conclusions from.
The core purposes of the death certification reforms are to introduce scrutiny of the cause of death to detect and deter malpractice, to improve reporting, and crucially to put the bereaved at the centre of the process by offering a conversation with the medical examiner about the cause of death. The expectation on doctors and medical examiners is clear, that they should complete certification as quickly and efficiently as possible, and the Department is working with all stakeholders to make sure this is the case.
Asked by: Ben Lake (Plaid Cymru - Ceredigion Preseli)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the adequacy of the retained margin element of the NHS drug tariff.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The adequacy of medicine margin that pharmacies are allowed to retain, with medicine margin being the difference between how much pharmacies are reimbursed and how much pharmacies were charged by suppliers, is currently being considered as part of the wider funding for the Community Pharmacy Contractual Framework.
Asked by: Ben Lake (Plaid Cymru - Ceredigion Preseli)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the adequacy of the (a) drug prices, (b) appliance prices and (c) fees paid to pharmacy contractors in the NHS Drug Tariff.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department undertakes a quarterly assessment of the adequacy of drug prices paid to community pharmacies through the medicine margin survey. The survey samples independent pharmacy contractors’ sales invoices for the medicines they dispense, and compares the amount paid with the amount reimbursed by the National Health Service. This has found that more than the amount agreed as part of the Community Pharmacy Contractual Framework has been delivered in total across the previous four financial years. Suppliers of appliances can optionally apply for an annual price increase on the NHS Drug Tariff. Fees in the tariff are routinely reviewed and updated when appropriate.
Medicine costs are considered as part of ongoing broader assessments of the financial health of the sector. However, if the selling price of a product goes above the reimbursement price in a given month, pharmacy contractors can request an increase to the reimbursement price from the Department via Community Pharmacy England. Where an increase is granted, this new price is known as a concessionary price. This ensures that that the reimbursement prices set are reflective of real time market selling prices, and means that pharmacy contractors are paid fairly for the medicines they dispense.
Asked by: Ben Lake (Plaid Cymru - Ceredigion Preseli)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help community pharmacies with increases in the cost of medications.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department undertakes a quarterly assessment of the adequacy of drug prices paid to community pharmacies through the medicine margin survey. The survey samples independent pharmacy contractors’ sales invoices for the medicines they dispense, and compares the amount paid with the amount reimbursed by the National Health Service. This has found that more than the amount agreed as part of the Community Pharmacy Contractual Framework has been delivered in total across the previous four financial years. Suppliers of appliances can optionally apply for an annual price increase on the NHS Drug Tariff. Fees in the tariff are routinely reviewed and updated when appropriate.
Medicine costs are considered as part of ongoing broader assessments of the financial health of the sector. However, if the selling price of a product goes above the reimbursement price in a given month, pharmacy contractors can request an increase to the reimbursement price from the Department via Community Pharmacy England. Where an increase is granted, this new price is known as a concessionary price. This ensures that that the reimbursement prices set are reflective of real time market selling prices, and means that pharmacy contractors are paid fairly for the medicines they dispense.
Asked by: Ben Lake (Plaid Cymru - Ceredigion Preseli)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of medication costs on community pharmacies.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department undertakes a quarterly assessment of the adequacy of drug prices paid to community pharmacies through the medicine margin survey. The survey samples independent pharmacy contractors’ sales invoices for the medicines they dispense, and compares the amount paid with the amount reimbursed by the National Health Service. This has found that more than the amount agreed as part of the Community Pharmacy Contractual Framework has been delivered in total across the previous four financial years. Suppliers of appliances can optionally apply for an annual price increase on the NHS Drug Tariff. Fees in the tariff are routinely reviewed and updated when appropriate.
Medicine costs are considered as part of ongoing broader assessments of the financial health of the sector. However, if the selling price of a product goes above the reimbursement price in a given month, pharmacy contractors can request an increase to the reimbursement price from the Department via Community Pharmacy England. Where an increase is granted, this new price is known as a concessionary price. This ensures that that the reimbursement prices set are reflective of real time market selling prices, and means that pharmacy contractors are paid fairly for the medicines they dispense.
Asked by: Ben Lake (Plaid Cymru - Ceredigion Preseli)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the reliability of diagnostic testing of blood samples for vCJD.
Answered by Maria Caulfield
Clinical diagnostic testing for variant Creutzfeldt-Jakob Disease (vCJD) is provided by the National Health Service, but there is currently no licensed blood screening test for vCJD, although there is ongoing research in this field. The National CJD Research and Surveillance Unit is involved in developing specialist investigations for vCJD, in collaboration with colleagues in Europe and internationally, with further information available at the following link:
https://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing
Asked by: Ben Lake (Plaid Cymru - Ceredigion Preseli)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions she has had with pharmaceutical companies on making the Covid vaccine commercially available.
Answered by Maria Caulfield
The Government is committed to protecting those most at risk from COVID-19 through vaccination, as guided by the Joint Committee on Vaccination and Immunisation (JCVI). Those eligible receive vaccination for free through the National Health Service. Whether and when a private market for COVID-19 vaccines emerges is a matter for private companies, and the Government has no formal role in this. However, the Government is supportive of the emergence of a private market for COVID-19 vaccines to increase choice for consumers. I have engaged with relevant interested parties who may seek to enter the private market this year, including vaccine manufacturers and pharmacies.
Asked by: Ben Lake (Plaid Cymru - Ceredigion Preseli)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 14 November 2023 to Question 395 on Coronavirus: Vaccination, what steps she is taking to implement the advice of the JCVI on the rollout of the autumn 2023 booster programme to people who are immunocompromised.
Answered by Maria Caulfield
As recommended by the Joint Committee on Vaccination and Immunisation (JCVI), the autumn 2023 COVID-19 vaccination programme includes all those aged between six months and 64 years old in a clinical risk group, as defined in tables 3 and 4 of the COVID-19 chapter of the Green Book. This includes those with immunosuppression.
We continue to work with NHS England and the UK Health Security Agency (UKHSA) to improve immunosuppressed uptake nationally, by understanding drivers of hesitancy, improving the quality of our published data, ensuring it is easy and convenient book and access vaccinations, and by continuing a variety of campaign activities throughout the winter including UKHSA’s ‘get winter strong’ campaign. This was launched on 1 November 2023 and encourages those eligible, specifically the clinically most vulnerable, who have not yet come forward for the flu and COVID-19 vaccines to do so.
NHS England has produced and shared a range of targeted communications materials encouraging people who are immunosuppressed to take up their offer of a COVID-19 booster vaccine, including posters, display screen visuals and social media cards. There are also materials to raise awareness that those who are a household contact of an immunosuppressed person are also eligible for vaccination. These materials have been translated into 28 languages to reach people from a wide range of communities through their native languages and have helped general practices, vaccination centres, pharmacies, and other sites to promote COVID-19 and flu vaccination this autumn/winter.
The Government’s Chief Medical Officer, Professor Sir Chris Whitty, also wrote to the main charities representing the clinically most vulnerable patient cohorts, to publicise this autumn’s campaign, and to enable them to signpost the offer to their patient communities.
The autumn campaign remains open and all those who are eligible but who have not yet come forward are encouraged to take up their vaccination.